The EluNIR Coronary Stent System
Raising the Bar on Drug-Eluting Stent Technology

Introducing the EluNIR Coronary Stent System, the next generation in drug-eluting stent technology. No other stent combines a unique metallic spring tip with an innovative dual-pattern strut design that advances deliverability in highly complex anatomy for outstanding clinical outcomes.

Exceptional Outcomes by Design
Drive Safely with Certainty

Whether faced with difficult lesions or calcifications, the EluNIR DES lives up to the promise of outstanding efficacy and safety results.

Exceptional Results in the BIONICS Pivotal Study

In BIONICS, a global more-comers’ randomized study of 1,919 patients at 76 sites, the EluNIR DES (n=958) demonstrated outstanding results including a 12 month Target Lesion Failure (TLF) of 5.4%, Target Lesion Revascularization (TLR) of 3.0%, and Late Stent Thrombosis of 0.0% while demonstrating non-inferiority to Resolute (n=961).

5.4% Target Lesion Failure at 12 Months

3.0% TLR at 12 Months

The BIONICS pivotal study had fewer exclusions of challenging patients than most pivotal studies on other stents. Patients with recent (<24 hours) ST-segment elevation myocardial infarction, left ventricular ejection fraction <30%, active stent thrombosis, creatinine clearance <30 mL/min, and prior PCI ≤12 months, and those unlikely to adhere to dual antiplatelet therapy, were excluded.

Even with this ‘more comers’ study design, the EluNIR DES demonstrated outstanding clinical outcomes.

Pioneering Cardiovascular Intervention

Cordis has partnered with Medinol to launch the EluNIR stent—an innovation designed to meet the unique demands of the ever-changing cardiovascular environment. Tapping more than 20 years of experience in the coronary stent space, these two innovative leaders are committed to raising the bar on the quality and performance of stenting systems to increase value to customers and the patients they serve.

With more than two million stents delivered globally, and decades of research, development, and manufacturing experience, Medinol’s cutting-edge cardiovascular intervention technology continues to demonstrate exceptional clinical results.

In NIREUS, a European pivotal study, the EluNIR DES demonstrated unprecedented results with an in-stent Late Loss of 0.04mm at 6 months (n=201).

The EluNIR DES was non-inferior to Resolute at 6 months for the primary angiographic endpoint.
No Stent Delivers More
Navigate with Superior Deliverability and Crossability

The EluNIR DES was designed to help you navigate with ease, even in highly complex anatomies. The unique metallic spring tip, narrow width struts and reinforced hypotube offer excellent pushability, agility and flexibility.

Enhanced Crossability
Spring tip enables force transfer designed for pushability, ease of placement, and kink resistance

Open Coils
Flexibility and agility to navigate through and around challenges

Polymer Jacket
Optimized for flexibility, pushability, and crossability

Improved Flexibility & Agility
The closed spring tip is designed to navigate through complex anatomy including tortuosity, calcification and previously implanted stents

Closed Coils
Enhanced pushability to cross complex lesions

Metallic Material
Will not buckle like plastic tips

Trackability & Tip Integrity
- Plastic tips used in most stents may incur flaring and gaping. Conversely, the EluNIR stent’s metallic spring tip closely hugs the wire on a curve, avoids flaring and gaping, and contributes to crossability.
- Extended length of shaft has hydrophilic coating which minimizes friction to improve deliverability

Thermo-Treated Reinforced Hypotube
- Reinforced hypotube for improved hub-to-tip force transfer, designed to navigate through tortuous anatomy without kinking
Delivering a Balanced Strut Design
Engineered for Conformability and Strength

No need to choose between strength or conformability. The EluNIR DES leverages a next generation smart stent design to combine the best of both worlds.

Innovative Dual-Pattern Strut Design

- **Thin Struts**: Designed for healing
  - 90 µm
- **Ultra-Narrow Width Struts**: Designed for conformability
  - 40 µm
- **Narrow Width Struts**: Designed for conformability
  - 72 µm

State-of-the-Art Polymer Technology

The EluNIR DES is the first and only drug-eluting stent coated with an elastomeric polymer that resists the cracking seen with other durable polymers. The durable elastomer coating is designed for long-term integrity.

- **Novel coating with elastic, non-cracking properties designed to reduce surface irregularities and deformations to provide a controlled drug elution.**
- **Optimal combination of coating process and design for predictable and uniform release of Ridaforolimus, a Rapamycin analogue.**

Lowest Metal Footprint

Strut to vessel contact matters. The EluNIR DES was designed to deliver the lowest Metal-to-Artery Ratio.

Low Metal-to-Tissue Contact Ratio

**Ultra-Narrow and Narrow Width Struts**

- **Ultra-Narrow Struts**: Thin Struts — 90 µm
  - Synergy
  - EluNIR
- **Narrow Width Struts**: Narrow to ultra-narrow width — 72 µm
  - Synergy
  - EluNIR
- **Xience**
- **Resolute Onyx**

**Lowest Metal-to-Tissue Contact Ratio**

- **Metal-to-Artery Ratio**: Percent of the vessel’s wall that is covered by the stent’s struts. The stent’s surface area is divided by the area of the vessel’s interior lumen.
- **The EluNIR DES boasts a unique scaffolding design and the narrowest strut width of any stent on the US market.**

Designed for Conformability

- **Uniform cell size**
- **Reduces the risk of tissue prolapse by maintaining a uniform scaffolding even on a curved vessel.**
- **When deployed on a curve other stents leave large gaps which could increase the risk for tissue prolapse and strut overlap.**

State-of-the-Art Polymer Technology

The EluNIR DES is the first and only drug-eluting stent coated with an elastomeric polymer that resists the cracking seen with other durable polymers. The durable elastomer coating is designed for long-term integrity.

- **Novel coating with elastic, non-cracking properties designed to reduce surface irregularities and deformations to provide a controlled drug elution.**
- **Optimal combination of coating process and design for predictable and uniform release of Ridaforolimus, a Rapamycin analogue.**

**Metal Footprint**

- **Data on file at Medinol.**
EluNIR
Ridaforolimus Eluting Coronary Stent System

For product in-service or support, contact your Cordis Sales Representative or call 800.327.7714.

<table>
<thead>
<tr>
<th>Stent Diameter (mm)</th>
<th>Stent Length (mm)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>8</td>
</tr>
<tr>
<td>3.00</td>
<td>LUN300R08US</td>
</tr>
</tbody>
</table>


For customer service, call 1.800.477.5801. For more information, visit cordis.com.

CAUTION: Federal (USA) law restricts this device to sale by or on the order of a physician. Stent implantation should only be performed by physicians who have received appropriate training. Prior to use, refer to the Instructions For Use supplied with this device for indications, contraindications, side effects, suggested procedure, warnings and precautions.

WARNINGS: Please ensure that the inner sterile package has not been opened, damaged or tampered with prior to use. The EluNIR Stent System is to be used for the treatment of lesions ≤30mm in length in arteries with reference diameters of 2.50mm to 4.25mm. The use of this device carries the associated risks of thrombosis, vascular complications and/or bleeding events. The use of this product outside of its approved indications for use may carry additional risks. This product should not be used in patients who are not likely to comply with the recommended antiplatelet therapy.

© 2017 Cardinal Health. All Rights Reserved. CORDIS and the Cordis LOGO are trademarks of Cardinal Health and may be registered in the US and/or in other countries. All other marks are the property of their respective owners. EluNIR is manufactured by Medinol and distributed by Cordis Corporation. 100507990 12/17